
Courtney Marabella joined the MJH Life Sciences team in 2021 and is Senior Editor for 

. Prior to joining the company she worked as the Audience Development Editor for the Asbury Park Press, part of the USA Today Network. 

Articles

The topical HDAC inhibitor remetinostat demonstrated favorable tolerability and clinically significant efficacy in reducing disease burden in patients with basal cell carcinoma, according to results from a phase 2 trial.

Topical Remetinostat Effective, Tolerable in Basal Cell Carcinoma

Morgan Petronelli is an associate editor for 

and joined the MJH Life Sciences team in December 2019. She graduated from Youngstown State University in 2019 with a bachelor's degree in journalism and a minor in political science. Prior to graduating, Morgan worked as the editor-in-chief of her college newspaper. She went on to work as an assignment editor at a broadcast news station in Youngstown, Ohio before joining 

She enjoys working out, listening to music, and playing with her dog Scout. You can reach her at 

Ilya Petrou, MD, is a contributing writer for 

Although JAK inhibitors have shown efficacy in treating challenging conditions, federal regulators continue their safety reviews.

FDA Warns About Some JAK Inhibitors

Podcasts

Mark Lebwohl, MD, takes a deep dive in the recent delay in approval for multiple JAK inhibitor drugs for treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis. He also discusses the impact of the delay, as well as the benefits of JAK inhibitors for inflammatory skin diseases, and an outlook for the future of this drug class.

The Cutaneous Connection: Episode 30- Impact of the JAK Inhibitor Approval Delays

The FDA is now requiring black box warning for certain JAK inhibitors used to treat arthritis. This news comes amid delay in FDA approval for multiple JAK inhibitors for the treatment of inflammatory skin conditions.  

FDA Requiring Black Box Warning for Certain JAK Inhibitors  

Ms. Hester is Content Specialist with Contemporary OB/GYN and Contemporary Pediatrics.

A phase 3 trial studied the effectiveness of oral abrocitinib along with topical therapy for moderate-to-severe atopic dermatitis in teens.

Abrocitinib and Topical Therapy Safe, Effective for Atopic Dermatitis in Teens

Armand Butera is the assistant editor for 

. He attended Fairleigh Dickinson University and graduated with a degree in communications with a concentration in journalism. Prior to graduating, Armand worked as the editor-in-chief of his college newspaper and a radio host for WFDU. He went on to work as a copywriter, freelancer, and human resources assistant before joining 

. In his spare time, he enjoys reading, writing, traveling with his companion and spinning vinyl records. Email him at 

A recent statement by Regeneron noted that chronic spontaneous urticaria is the fifth disease associated with positive Phase 3 results involving the monoclonal antibody.

Dupilumab Improves Chronic Spontaneous Urticaria Symptoms

and joined the MJH Life Sciences team in April 2021. She graduated from Kent State University in 2018 with a bachelor's degree in journalism and a minor in sociology. Linda used to work as a creative writer for 

 and was a technical writer/regulatory specialist/purchasing agent at GM Industrial before coming on to the team. She enjoys reading, traveling, and learning new perspectives. You can reach her at 

The FDA has granted priority review to Merck’s application for pembrolizumab, a treatment for melanoma. 

FDA Sets PDUFA Date for Pembrolizumab

UCB announced that more than 90% of patients treated with bimekizumab have maintained IGA 1/0 results in their long-term BE BRIGHT trial. 

Bimekizumab Demonstrates Positive Long-term in Phase 3 Psoriasis Trial

The FDA has accepted the New Drug Application (NDA) for tapinarof as a treatment for plaque psoriasis in adults and set the PDUFA target action date to Q2 2022.

FDA Accepts New Drug Application for Tapinarof in Plaque Psoriasis

Videos

Mark Lebwohl, MD, explains the recent delay in approval of JAK inhibitors by the FDA, how it is affecting the inflammatory skin disease community, and if physicians should be concerned.

Drug Watch